| Company Name: | Idenix Pharmaceuticals, Inc. | | Ticker Symbol: | IDIX | | | WWW Address: | www.idenix.com | | CEO: | Dr. Jean-Pierre Sommadossi, Ph.D. | | No. of Employees: | 173 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.92 |  0.0 | 1.64 | 2.19 | 1.94 | 1.95 | 1.90 | 58609 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 127.4 | 66.3 | 0.53 | -1.24 | 0.00 | 0.0 | 0.0 | 6.82 - 1.81 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.92 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 127.4 | mil |
| Latest Shares Outstanding | 66.3 | mil |
| Earnings pS (EPS) | -1.24 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 58,087 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 56.6 | mil |
| Float as % of Shares Outstanding | 95.9 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 161.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 314.70 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -60.3 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -274.0 | % |
| Current Ratio | 3.3 | |
| Leverage Ratio (Assets/Equity) | 15.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 2.39 | |
| LT Debt/Total Capital | 70.0 | % |
| Working Capital pS | 0.66 | $ |
| Cash pS | 0.90 | $ |
| Book-Value pS | 0.09 | $ |
| Tangible Book-Value pS | -0.08 | $ |
| Cash Flow pS | -0.75 | $ |
| Free Cash Flow pS | -0.55 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 21.56 | |
| Price/Tangible Book Ratio | -22.71 | |
| Price/Cash Flow | -2.6 | |
| Price/Free Cash Flow | -3.5 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 4.3 | 103 | 1,277 | 3,032 |
| 4 Weeks | 2.45 | 1.81 | 2.22 | -13.5 | 81 | 1,848 | 33,262 |
| 13 Weeks | 3.46 | 1.81 | 3.16 | -39.2 | 56 | 1,731 | 107,347 |
| 26 Weeks | 5.45 | 1.81 | 3.40 | -43.5 | 47 | 1,990 | 250,678 |
| 52 Weeks | 6.82 | 1.81 | 5.79 | -66.8 | 27 | 1,747 | 436,688 |
| YTD | 6.78 | 1.81 | - | -66.8 | 27 | 1,759 | 401,130 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.87 | 1.90 | 2.56 | 3.13 | 3.21 | 0.53 | 0.45 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -33.14 | 68.6 | -45.88 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 1.60 | NA | -29.47 |
| R&D | -8.62 | NA | -21.41 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 65.5 | 44.8 | -85.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.32 | 0.12 | 0.23 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 38.19 |
| Current Ratio | 2.6 |
| Quick Ratio (Acid Test) | 2.4 |
| Liquidity Ratio (Cash) | 2.21 |
| Receivables Turnover | 1.3 |
| Average Collection Period | 277 |
| Working Capital/Equity | 414.3 |
| Working Capital pS | 0.54 |
| Cash-Flow pS | -1.15 |
| Free Cash-Flow pS | -1.15 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -2.61 |
| Financial Leverage Ratio (Assets/Equity) | 10.8 |
| Debt Ratio | 90.8 |
| Total Debt/Equity (Gearing Ratio) | 1.74 |
| LT Debt/Equity | 1.74 |
| LT Debt/Capital Invested | 262.4 |
| LT Debt/Total Liabilities | 17.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.48 |
| Tobin's Q Ratio | 1.60 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.32 |
| Enterprise Value (EV)/Free Cash Flow | -1.45 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -22.71 |
| Price/Book Ratio - LTM | 21.56 |
| Price/Cash Flow Ratio | -2.6 |
| Price/Free Cash Flow Ratio - LTM | -3.5 |
| Price/Sales Ratio | 9.21 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.23 |
| Current Liabilities pS | 0.35 |
| Tangible Book Value pS - LTM | -0.08 |
| Book Value pS - LTM | 0.09 |
| Capital Invested pS | 0.30 |
| Cash pS - LTM | 0.90 |
| Cash Flow pS - LTM | -0.75 |
| Free Cash Flow pS - LTM | -0.55 |
| Earnings pS (EPS) | -1.24 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -646.87 |
| Free Cash Flow Margin 5YEAR AVG | -193.33 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | -93.2 |
| Equity Productivity | 1.37 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.50 |
| Return on Capital Invested (ROCI) | -348.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -50.1 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -88.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -30.5 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -94.5 |
| Effective Tax Rate | 2.8 |
| Effective Tax Rate - 5YEAR AVRG. | 2.7 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 158 |
| Revenue per Employee | 58,087 |
| Net Income per Employee | -405,815 |
| Average Collection Period | 158 |
| Receivables Turnover | 1.3 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 38.49 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.33 |
| Fixed Assets Turnover | 0.34 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.24 |
| Revenue per $ Plant | 0.76 |
| Revenue per $ Common Equity | 1.37 |
| Revenue per $ Capital Invested | 0.50 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 270.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 67.0 |
| Research & Devlopment (R&D) as % of Revenue | 536.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 536.2 |
|
|  
|
| |
 |  |